FDA Warns Against Long Term Use of Reglan

The Food and Drug Adminstration is requiring that manufacturers of Reglan® (metoclopramide) to add a boxed warning to its label.  Long term or high dose use can lead to tardive dyskinesia, involuntary and repetitive movements of the body, even after the drug is discontinued. FDA will also require the development of a risk evaluation and mitigation…  Read More